text stringlengths 0 197k |
|---|
Ideation: Adolescent patients with current suicidal ideation. Clinical Population: Psychological or psychiatric patients of the same age and gender without suicidal ideation. |
General Population: Adolescents without known psychological or psychiatric pathology of the same age and gender, without suicidal ideation. |
Researchers will compare these groups to determine if the AI algorithm is effective in differentiating individuals with suicidal ideation (Group 1) from both a clinical control group (Group 2) and a general population control group (Group 3) using the collected multimodal data. The study aims to assess the algorithm's ... |
<|newrecord|> nctId: NCT06341621 id: SCHBCC-N071 briefTitle: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib acronym: Rainbow overallStatus: RECRUITING date: 2024-04-02 date: 2027-02-25 date: 2029-01-01 date: 2024-04-02 date: 2024-04-10 name: Fudan ... |
<|newrecord|> nctId: NCT06341608 id: K23DA057528 type: NIH link: https://reporter.nih.gov/quickSearch/K23DA057528 briefTitle: Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention overallStatus: RECRUITING date: 2023-12-08 date: 2028-04 date: 2028-04 date:... |
The specific aims are to: 1) identify components of an effective telehealth intervention and barriers to implementation, 2) partner with an advisory board of OUD treatment stakeholders from different settings to develop a telehealth intervention for OUD treatment with buprenorphine, and 3) conduct a pilot trial of the ... |
The investigators will enroll 60 patients, 30 individuals who are currently enrolled in in-person OUD treatment with buprenorphine, with a treatment episode duration of 1-3 months, and 30 individuals who are not currently receiving OUD treatment but approved for treatment intake at buprenorphine clinic by an OUD treatm... |
<|newrecord|> nctId: NCT06341595 id: 123322 briefTitle: Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM overallStatus: RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-02 date: 2024-04-02 name: The First Affiliated Hospital with Nanjing M... |
Patients will receive sintilimab Injection (200mg iv q3w d1) combined with concurrent radiotherapy and chemotherapy. The chemotherapy regimen will use oxaliplatin 130mg/m2+S-1 40mg/m2 bid d1-14. Radiotherapy is performed using intraperitoneal radiation therapy, once a day, five times a week, at a dose of 1.8-2 Gy/f, fo... |
<|newrecord|> nctId: NCT06341582 id: 2023-10-14 briefTitle: Prediction and Evaluation by ETCOc of Neonatal Hyperbilirubinemia Cohort acronym: PREVENT overallStatus: RECRUITING date: 2023-12-11 date: 2025-11 date: 2025-11 date: 2024-04-02 date: 2024-04-02 name: Guangzhou Women and Children's Medical Center class: OTHER ... |
<|newrecord|> nctId: NCT06341569 id: 11/07.03.2024 briefTitle: Physical Therapy Students: Well-being overallStatus: NOT_YET_RECRUITING date: 2024-04-11 date: 2024-08-29 date: 2024-10-30 date: 2024-04-02 date: 2024-04-10 name: University of Medicine and Pharmacy "Victor Babes" Timisoara class: OTHER briefSummary: This s... |
Intervention group: second-year physical therapy students participating in a 14-week breathing techniques program. |
Control group: second-year physical therapy students who do not participate in the program but complete the same questionnaires. |
Comparison groups: 1st, 2nd, and 3rd year physical therapy students participating in assessments only. primaryPurpose: SCREENING masking: NONE count: 150 type: ESTIMATED name: Respiratory breathing techniques group measure: Assessing intrinsic and extrinsic motivation levels among physical therapy students. measure: As... |
<|newrecord|> nctId: NCT06341556 id: iNHL-03 briefTitle: A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma overallStatus: RECRUITING date: 2024-04 date: 2026-03 date: 2028-06 date: 2024-04-02 date: 2024-04-02 name: Fudan University class: OTHER briefSummary... |
<|newrecord|> nctId: NCT06341543 id: QUANTIFOT id: PHRCI-2021-68 type: OTHER_GRANT domain: DGOS (France) briefTitle: Quantiferon CMV to Identify Treatment Need For Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT) acronym: QUANTIFOT overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2026-06-15 d... |
Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. |
Most of available treatment display adverse effects that limit their use. Therefore, in case of an infection, it is of primary importance to identify the patients at high risk of severe infection and/or disease, and who ill benefit the most from antiviral therapy. |
As CMV infection is mainly controlled by cellular immunity, measuring specific anti-CMV T lymphocyte immunity could be an interesting tool for identifying these at-risk individuals. One of these tests is the QuantiFERON-CMV (QF-CMV) assay (QuiagenTM, Courtabœuf, France). |
Aim of the study |
The aim of the study is to determine the extent to which the QF-CMV can be use to identify, among SOT recipients with a CMV viremia, those that may not need antiviral therapy. |
Methods |
Participation to the study will be proposed to SOT recipients with an asymptomatic CMV infection with a blood viral load between 1,000 and 15,000 IU/mL. |
The QF-CMV will be performed in included participants, and the result will be given or not to the clinician in charge (according to the attributed group through randomisation). |
* In the group without result communication, the clinician in charge will determine whether a treatment is needed according to the guidelines and the local practices. |
* in the group with result communication, the clinician in charge will be advised not to introduce antiviral therapy if the result is positive, and to determine whether a treatment is needed according to the guidelines and the local practices if the result is positive. |
In the following weeks, the viral load will be monitored, along with creatininemia, cell blood count, and kalemia (to detect antiviral adverse effect). |
The participants will be sampled: |
* 5 to 12 days after QF-CMV sampling (V2) ; |
* 7 to 14 days days after V2 (V3 - between D12 and D26) ; |
* 7 to 14 days days after V3 (V4 - between D19 and D40) . |
Endpoints |
The primary endpoint is the rate of uncontrolled infection 5 to 12 days after QF-CMV sampling, defined as follows: |
* Blood CMV viral load \>10,000 IU/mL \[4 log\]; |
* And/or increase in blood viral load ≥0.5 log IU/mL with CV otherwise \>5000 IU/mL; |
* And/or the onset of CMV disease. |
The secondary endpoint is the is the occurrence antiviral adverse effects (hematoxicity or nephrotoxicity). conditions: Cytomegalovirus Infections conditions: Heart Transplantation conditions: Kidney Transplantation conditions: Lung Transplantation conditions: Liver Transplantation studyType: INTERVENTIONAL phases: NA ... |
<|newrecord|> nctId: NCT06341530 id: SURPASS-1 briefTitle: Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer overallStatus: RECRUITING date: 2024-01-31 date: 2024-12-31 date: 2025-12-31 date: 2024-04-02 date: 2024-04-02 name: The First Affiliated Hospital of Zhengzhou Uni... |
This study intends to treat patients with advanced non-small cell lung cancer (NSCLC) confirmed by pathology with the combination of anlotinib and penpulimab injection, and observe the efficacy and safety of anlotinib and penpulimab injection in the first and second lines of NSCLC. This study is expected to provide a r... |
<|newrecord|> nctId: NCT06341517 id: IRB_in_progress briefTitle: Brain Circuitry Therapeutics for Schizophrenia acronym: ATHENA overallStatus: NOT_YET_RECRUITING date: 2024-11-05 date: 2026-01-05 date: 2027-12-12 date: 2024-04-02 date: 2024-04-02 name: Indrit Begue class: OTHER briefSummary: This project is a double bl... |
<|newrecord|> nctId: NCT06341504 id: ALVMsg2023 id: 263472 type: OTHER_GRANT domain: Fonds de recherche du Québec - Société et culture briefTitle: Prevention Messages for EGMs: Effects on Behaviours and Cognitions overallStatus: RECRUITING date: 2024-02-27 date: 2024-09 date: 2024-09 date: 2024-04-02 date: 2024-04-02 n... |
After answering a series of short questionnaires by phone, participants are asked to schedule a gambling session which is done in a laboratory on the university's campus. This laboratory replicates a typical bar, and is equipped with real EGMs. Participants are recruited under the false pretense of giving their opinion... |
After having stopped by their own volition (some exceptions apply, see "Detailed Description" for further details), participants are debriefed on the real goals of this study and reimbursed any incurred losses while gambling. They are then be asked to answer another series of questionnaires. conditions: Gambling studyT... |
* Experimental: Regular gambling session + Prevention pop-up messages |
* Active Comparator: Regular gambling session |
Three assessment phases: |
* Pre-experiment. Telephone interview before the gambling session. Measures baseline characteristics and schedule the gambling session. Usually done within a couple of days following an application to participate. |
* Experiment. Gambling session in the laboratory. Behaviour is continuously measured starting with the first time the participant puts money in the EGM to participant choosing to end their gambling session. Duration is limited to 2 hrs (unbeknownst to participant). Session is scheduled days to weeks after the Pre-exper... |
* Post-experiment. Debriefing and post-experiment interview. Done right after the gambling session is ended. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants are recruited under the false pretense of evaluating the realism of a gambling session in a laboratory replicating a bar environment. W... |
Note that masking becomes "open label" after debriefing. Indeed, after being informed of the true goals of this study, participants will easily be able to determine in which group they were assigned based on what occured during their gambling session. Though, gambling behaviours are recorded before debriefing and won't... |
There is no functional way to mask group assignment to the members of the research team. However, the randomization procedure assures that allocation is purely random. whoMasked: PARTICIPANT count: 80 type: ESTIMATED name: Prevention pop-up messages name: Mandatory time limit name: Responsible gambling information name... |
<|newrecord|> nctId: NCT06341491 id: obs. Delay Discounting briefTitle: The Study of Delay Discounting Among Beneficiaries of the Pé-de-Meia Program overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-04-30 date: 2025-12-01 date: 2024-04-02 date: 2024-04-02 name: Federal Institute of Education, Science and Te... |
How does the "Pé-de-Meia" Program affect the students' propensity for delay discounting? Is there a relationship between the level of delay discounting among students, their academic performance, and school attendance? Participants in the study, high school students enrolled in the "Pé-de-Meia" Program, will undergo as... |
<|newrecord|> nctId: NCT06341478 id: IG-2022-27746 briefTitle: Investigator Grant (IG) 2022 27746 overallStatus: RECRUITING date: 2024-03-15 date: 2026-03-15 date: 2027-03-15 date: 2024-04-02 date: 2024-04-02 name: IRCCS San Raffaele class: OTHER briefSummary: Background: |
Muscle-invasive bladder cancer (MIBC) is a systemic disease as \>40% of patients (pts) ultimately develop recurrence after radical cystectomy (RC). For pts who cannot receive or refuse cisplatin-based chemotherapy there is no standard-of-care neoadjuvant therapy. Single-agent pembrolizumab, given neoadjuvantly in patie... |
Hypothesis: |
By developing a robust biomarker program associated with therapeutic benefit of novel therapies or their combinations, along with an imaging biomarker development, the investigators will be able to identify suitable tumor characteristics for personalizing perioperative therapies in MIBC, coupled with the possibility to... |
Aims: |
The project is aimed at characterizing the tumor and microenvironment characteristics of muscle-invasive bladder cancer, with a special focus on their changes induced by various neoadjuvant therapies preceding radical cystectomy. |
The investigators will aim to evaluate the tumor and immune profile on matched pre- vs post-therapy samples and noninvasively monitor the response to treatment with the use of radiological assessments. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.